CVD Risk Prediction: The Evolving Role of Laboratory Testing


Price: $0.00

Register for this program and hear Dr. Paul Ridker explain how the set of cholesterol management guidelines released by the AHA and ACC in 2013 are changing the way clinicians approach CVD risk assessment and the management of at-risk patients using statin therapy. Dr. Ridker will discuss how the new risk calculator that accompanied the guidelines differs from traditional risk prediction models such as the Framingham Risk Score; current thinking on the most effective way to assess a patient's CVD risk; and how lipid assays and markers of inflammation are expected to be used in CVD risk assessment now and in the future.